Can	O
mean	B:C0200665
platelet	I:C0200665
volume	I:C0200665
be	O
used	O
as	O
a	O
biomarker	O
for	O
asthma	O
?.	O

Can	O
mean	O
platelet	I:C0200665
volume	I:C0200665
be	O
used	O
as	O
a	O
biomarker	B:C0005516
for	O
asthma	O
?.	O

Can	O
mean	O
platelet	I:C0200665
volume	I:C0200665
be	O
used	O
as	O
a	O
biomarker	O
for	O
asthma	B:C0004096
?.	O

Platelets	B:C0005821
play	O
important	O
roles	O
in	O
airway	O
inflammation	I:C0004096
and	O
are	O
activated	O
in	O
inflammatory	O
lung	I:C4230430
diseases	I:C4230430
,	O
including	O
asthma	O
.	O

Platelets	O
play	O
important	O
roles	O
in	O
airway	B:C0004096
inflammation	I:C0004096
and	O
are	O
activated	O
in	O
inflammatory	O
lung	I:C4230430
diseases	I:C4230430
,	O
including	O
asthma	O
.	O

Platelets	O
play	O
important	O
roles	O
in	O
airway	O
inflammation	I:C0004096
and	O
are	O
activated	O
in	O
inflammatory	B:C4230430
lung	I:C4230430
diseases	I:C4230430
,	O
including	O
asthma	O
.	O

Platelets	O
play	O
important	O
roles	O
in	O
airway	O
inflammation	I:C0004096
and	O
are	O
activated	O
in	O
inflammatory	O
lung	I:C4230430
diseases	I:C4230430
,	O
including	O
asthma	B:C0004096
.	O

We	O
evaluated	B:C0220825
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	B:C0200665
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	B:C0200665
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	B:C0005516
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	B:C0032173
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	B:C0004096
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	B:C0231221
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	B:C4086268
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	B:C0200665
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	B:C0021212
of	O
inflammation	O
.	O

We	O
evaluated	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
mean	O
platelet	I:C0200665
volume	I:C0200665
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	I:C0032173
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
mean	O
platelet	I:C0200665
volume	I:C0200665
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	B:C0021368
.	O

Our	O
patient	O
group	O
consisted	O
of	O
95	O
children	O
with	O
exacerbation	B:C0349790
of	I:C0349790
asthma	I:C0349790
who	O
were	O
admitted	O
to	O
our	O
allergy	O
clinic	I:C3810819
.	O

Our	O
patient	O
group	O
consisted	O
of	O
95	O
children	O
with	O
exacerbation	O
of	I:C0349790
asthma	I:C0349790
who	O
were	O
admitted	B:C0184666
to	O
our	O
allergy	O
clinic	I:C3810819
.	O

Our	O
patient	O
group	O
consisted	O
of	O
95	O
children	O
with	O
exacerbation	O
of	I:C0349790
asthma	I:C0349790
who	O
were	O
admitted	O
to	O
our	O
allergy	B:C3810819
clinic	I:C3810819
.	O

The	O
control	O
group	O
consisted	O
of	O
100	O
healthy	O
children	O
matched	B:C0150103
for	O
age	O
,	O
gender	O
,	O
and	O
ethnicity	O
.	O

Mean	B:C0200665
platelet	I:C0200665
volume	I:C0200665
values	O
of	O
the	O
patient	O
group	O
obtained	O
during	O
exacerbation	O
of	I:C0349790
asthma	I:C0349790
were	O
compared	O
to	O
those	O
of	O
the	O
same	O
group	O
during	O
the	O
asymptomatic	O
period	O
and	O
with	O
the	O
control	O
group	O
.	O

Mean	O
platelet	I:C0200665
volume	I:C0200665
values	O
of	O
the	O
patient	O
group	O
obtained	O
during	O
exacerbation	B:C0349790
of	I:C0349790
asthma	I:C0349790
were	O
compared	O
to	O
those	O
of	O
the	O
same	O
group	O
during	O
the	O
asymptomatic	O
period	O
and	O
with	O
the	O
control	O
group	O
.	O

Mean	O
platelet	I:C0200665
volume	I:C0200665
values	O
of	O
the	O
patient	O
group	O
obtained	O
during	O
exacerbation	O
of	I:C0349790
asthma	I:C0349790
were	O
compared	O
to	O
those	O
of	O
the	O
same	O
group	O
during	O
the	O
asymptomatic	B:C0231221
period	O
and	O
with	O
the	O
control	O
group	O
.	O

We	O
investigated	O
factors	O
that	O
can	O
affect	O
the	O
mean	B:C0200665
platelet	I:C0200665
volume	I:C0200665
values	O
of	O
asthma	O
patients	O
,	O
including	O
infection	O
,	O
atopy	O
,	O
immunotherapy	O
treatment	I:C0021083
,	O
and	O
severity	O
of	O
asthma	O
exacerbation	I:C0038218
.	O

We	O
investigated	O
factors	O
that	O
can	O
affect	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
values	O
of	O
asthma	B:C0004096
patients	O
,	O
including	O
infection	O
,	O
atopy	O
,	O
immunotherapy	O
treatment	I:C0021083
,	O
and	O
severity	O
of	O
asthma	O
exacerbation	I:C0038218
.	O

We	O
investigated	O
factors	O
that	O
can	O
affect	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
values	O
of	O
asthma	O
patients	O
,	O
including	O
infection	B:C3714514
,	O
atopy	O
,	O
immunotherapy	O
treatment	I:C0021083
,	O
and	O
severity	O
of	O
asthma	O
exacerbation	I:C0038218
.	O

We	O
investigated	O
factors	O
that	O
can	O
affect	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
values	O
of	O
asthma	O
patients	O
,	O
including	O
infection	O
,	O
atopy	B:C0392707
,	O
immunotherapy	O
treatment	I:C0021083
,	O
and	O
severity	O
of	O
asthma	O
exacerbation	I:C0038218
.	O

We	O
investigated	O
factors	O
that	O
can	O
affect	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
values	O
of	O
asthma	O
patients	O
,	O
including	O
infection	O
,	O
atopy	O
,	O
immunotherapy	B:C0021083
treatment	I:C0021083
,	O
and	O
severity	O
of	O
asthma	O
exacerbation	I:C0038218
.	O

We	O
investigated	O
factors	O
that	O
can	O
affect	O
the	O
mean	O
platelet	I:C0200665
volume	I:C0200665
values	O
of	O
asthma	O
patients	O
,	O
including	O
infection	O
,	O
atopy	O
,	O
immunotherapy	O
treatment	I:C0021083
,	O
and	O
severity	O
of	O
asthma	B:C0038218
exacerbation	I:C0038218
.	O

Mean	O
mean	B:C0200665
platelet	I:C0200665
volume	I:C0200665
values	O
in	O
the	O
exacerbation	O
period	O
,	O
the	O
healthy	O
period	O
,	O
and	O
in	O
the	O
control	O
group	O
were	O
8.1	O
±0.8	O
fl	O
,	O
8.1	O
±	O
1.06	O
fl	O
,	O
and	O
8.2	O
±0.9	O
fl	O
,	O
respectively	O
;	O
there	O
were	O
no	O
significant	I:C1273937
differences	O
between	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Mean	O
mean	O
platelet	I:C0200665
volume	I:C0200665
values	O
in	O
the	O
exacerbation	B:C4086268
period	O
,	O
the	O
healthy	O
period	O
,	O
and	O
in	O
the	O
control	O
group	O
were	O
8.1	O
±0.8	O
fl	O
,	O
8.1	O
±	O
1.06	O
fl	O
,	O
and	O
8.2	O
±0.9	O
fl	O
,	O
respectively	O
;	O
there	O
were	O
no	O
significant	I:C1273937
differences	O
between	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Mean	O
mean	O
platelet	I:C0200665
volume	I:C0200665
values	O
in	O
the	O
exacerbation	O
period	O
,	O
the	O
healthy	O
period	O
,	O
and	O
in	O
the	O
control	O
group	O
were	O
8.1	O
±0.8	O
fl	O
,	O
8.1	O
±	O
1.06	O
fl	O
,	O
and	O
8.2	O
±0.9	O
fl	O
,	O
respectively	O
;	O
there	O
were	O
no	B:C1273937
significant	I:C1273937
differences	O
between	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
severity	O
of	O
asthma	B:C0004096
,	O
severity	O
of	O
asthma	O
exacerbation	I:C0349790
,	O
immunotherapy	O
,	O
coinfection	O
,	O
eosinophil	O
count	I:C0750879
,	O
and	O
IgE	O
level	O
also	O
had	O
no	O
effect	O
on	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
severity	O
of	O
asthma	O
,	O
severity	O
of	O
asthma	B:C0349790
exacerbation	I:C0349790
,	O
immunotherapy	O
,	O
coinfection	O
,	O
eosinophil	O
count	I:C0750879
,	O
and	O
IgE	O
level	O
also	O
had	O
no	O
effect	O
on	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
severity	O
of	O
asthma	O
,	O
severity	O
of	O
asthma	O
exacerbation	I:C0349790
,	O
immunotherapy	B:C0021083
,	O
coinfection	O
,	O
eosinophil	O
count	I:C0750879
,	O
and	O
IgE	O
level	O
also	O
had	O
no	O
effect	O
on	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
severity	O
of	O
asthma	O
,	O
severity	O
of	O
asthma	O
exacerbation	I:C0349790
,	O
immunotherapy	O
,	O
coinfection	B:C0275524
,	O
eosinophil	O
count	I:C0750879
,	O
and	O
IgE	O
level	O
also	O
had	O
no	O
effect	O
on	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
severity	O
of	O
asthma	O
,	O
severity	O
of	O
asthma	O
exacerbation	I:C0349790
,	O
immunotherapy	O
,	O
coinfection	O
,	O
eosinophil	B:C0750879
count	I:C0750879
,	O
and	O
IgE	O
level	O
also	O
had	O
no	O
effect	O
on	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
severity	O
of	O
asthma	O
,	O
severity	O
of	O
asthma	O
exacerbation	I:C0349790
,	O
immunotherapy	O
,	O
coinfection	O
,	O
eosinophil	O
count	I:C0750879
,	O
and	O
IgE	B:C0020846
level	O
also	O
had	O
no	O
effect	O
on	O
mean	O
platelet	I:C0200665
volume	I:C0200665
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
severity	O
of	O
asthma	O
,	O
severity	O
of	O
asthma	O
exacerbation	I:C0349790
,	O
immunotherapy	O
,	O
coinfection	O
,	O
eosinophil	O
count	I:C0750879
,	O
and	O
IgE	O
level	O
also	O
had	O
no	O
effect	O
on	O
mean	B:C0200665
platelet	I:C0200665
volume	I:C0200665
(	O
p	O
>	O
0.05	O
)	O
.	O

Although	O
platelets	B:C0005821
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
asthma	O
,	O
MPV	O
measurement	I:C0200665
is	O
insufficient	O
to	O
detect	O
inflammation	O
through	O
platelets	O
.	O

Although	O
platelets	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
asthma	B:C0004096
,	O
MPV	O
measurement	I:C0200665
is	O
insufficient	O
to	O
detect	O
inflammation	O
through	O
platelets	O
.	O

Although	O
platelets	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
asthma	O
,	O
MPV	B:C0200665
measurement	I:C0200665
is	O
insufficient	O
to	O
detect	O
inflammation	O
through	O
platelets	O
.	O

Although	O
platelets	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
asthma	O
,	O
MPV	O
measurement	I:C0200665
is	O
insufficient	O
to	O
detect	B:C1511790
inflammation	O
through	O
platelets	O
.	O

Although	O
platelets	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
asthma	O
,	O
MPV	O
measurement	I:C0200665
is	O
insufficient	O
to	O
detect	O
inflammation	B:C0021368
through	O
platelets	O
.	O

Although	O
platelets	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
asthma	O
,	O
MPV	O
measurement	I:C0200665
is	O
insufficient	O
to	O
detect	O
inflammation	O
through	O
platelets	B:C0005821
.	O

